BPC-157 sourcing guide for compounding pharmacies

BPC-157 sits at the intersection of intense clinical interest and unsettled regulation. For compounding pharmacy procurement teams, the right supplier conversation looks very different from a research-only catalog purchase.

This guide outlines a five-step due diligence process we recommend before placing your first commercial-scale order.

1. Ask for a sample COA before pricing

Any supplier worth working with can hand you a batch-specific Certificate of Analysis at the inquiry stage. The COA should specify:

• HPLC purity (≥99%)
• Mass-spec confirmation of molecular weight
• Water content
• Residual solvents and counter-ion (acetate / TFA)
• Microbial limits + endotoxin (LAL) for injectable applications

2. Test sequence verification

Request the sequence report from at least one batch. BPC-157 is the 15-mer GEPPPGKPADDAGLV. If the supplier cannot deliver a verified sequence, you have an identity problem before you have a quality problem.

3. Review stability data

Accelerated stability (40°C / 75% RH) and long-term (real-time) data should be available on request. If the supplier offers neither, the lyophilized cake's behavior at your downstream conditions is unproven.

4. Validate the regulatory profile

For US compounding pharmacies, BPC-157 is currently under FDA PCAC review for the 503A bulks list. Your supplier should be aware of the regulatory trajectory and able to explain how their documentation aligns with the bulks-list requirements (USP/NF monograph, FDA-registered facility, valid COA).

5. Run a pilot lot

Before scaling to recurring orders, place a pilot purchase (typically 100–500 vials). Run your internal QC on that lot, validate it under your dispensing conditions, and confirm the COA matches your downstream assays.

PeptideXpo welcomes pilot inquiries — request a quote and our regulatory team will share sample documentation within 12 hours.